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1,2 These patients require additional therapy approaches after achieving remission with multimodal chemotherapy. Allogeneic haematopoietic stem cell transplantation (SCT) shows promising results mainly due to an immunological antileukaemic control by the graftversus-leukaemia effect (GVL), but treatment-related mortality (TRM) remains a serious problem of the method. [3] [4] [5] [6] To investigate the value of SCT, the BFM Study Group initiated a multicentre, controlled, prospective study enrolling all paediatric patients with ALL in first, second or subsequent remission with a high risk for relapse defined by cytogenetic characteristics, the response to the induction chemotherapy and the time and site of relapse, respectively.
The main objectives of the study are to investigate whether SCT from a closely HLA-matched related or unrelated donor ('matched donor' -MD) is equivalent to the SCT from HLA-identical matched sibling donors (MSD), to evaluate the efficacy of SCT from HLAmismatched donors (MMD) as compared to SCT from MSD/MD and to prospectively evaluate and compare the incidence of acute and chronic GvHD after SCT (see Table 3 ).
Indication

CR1
Only a particular subgroup of patients with a very high risk for relapse (see Table 1 ) is eligible for transplantation. In most situations, only MSD and MD are accepted as possible donors; in some patients with extremely high risk for relapse also an MMD can be recruited.
CR2
In relapsed ALL, patients are subdivided into risk groups according to the parameters time to relapse, site of relapse and immunophenotype. High-risk patients (early isolated or very early isolated/combined bone marrow (BM) relapse of a B-cell precursor (BCP) ALL; any BM involving relapse of a T-lineage ALL) are eligible for any allogeneic SC donor. Intermediate-risk patients (early or late combined BM relapse, late isolated BM relapse of a BCP ALL) are eligible for an MSD or an MD (but not for an MMF/UD) if MRD of more than 10 À3 after the second induction course can be detected (Table 2 ).
CR3
Patients with ALL in CR3 have a very high risk for subsequent relapse with chemotherapy alone; however, SCT is associated with a very high risk for TRM due to the pre-existing high cumulative organ toxicity. The adequate post-remission therapy in this context remains to be determined; however, if a MSD or an MD is available, SCT is regarded as a reasonable option. For patients without an HLA-matched donor, in our opinion, MMD transplantation with very high cell numbers and avoidance of immune suppression post transplant could enhance the chance for cure.
Donor selection
Well matched donors provide better results. There is no doubt that transplantation from an HLA-identical sibling donor is the gold standard for the outcome of SCT in indicated situations. In a retrospective analysis of 103 ALL patients in CR2 with sibling donors prepared with total body irradiation (TBI) and VP16, an EFS of 0.6170.05 could be achieved (A von Stackelberg, personal communication). Recent data demonstrate clearly that mismatching on allele level is connected with higher risk of transplant rejection, nonengraftment, acute and chronic GvHD and TRM. [7] [8] [9] These analyses lead to the conclusion that donors typed with high-resolution techniques on an allele level may result in better outcome comparable to sibling donor transplantation. Therefore, we have developed a list of recommendations as to which donors are acceptable (see Table 3 ) in the different disease categories. In addition, there is a list of priorities, which allow identifying the best donor, if multiple donors at the same level of matching are available, including CMV serostatus, age and sex of donor and recipient.
Conditioning regimen
It could be shown in various studies that the choice of conditioning had a significant impact on the survival and the incidence of relapse. 10, 11, 13 Dopfer et al 12 showed in a retrospective analysis that the conditioning with TBI/VP16 is superior to other conditioning regimens. A similar long-term survival was achieved with a conditioning consisting of ARA-C, melphalan and TBI. 14 The conditioning with BU/CYCLO/MEL, however, showed a high TRM and a high risk of relapse. Thus, irradiation-free conditioning regimens could not provide similarly high remission rates as the ones with TBI/VP16.
In the current concept, fractionated TBI and etoposide build the backbone of the conditioning regimen. For those patients who cannot receive TBI, either because of their age or because they have already received high irradiation doses before SCT, only busulphan can be used as myeloablative drug. In the MMD setting, additionally to TBI or busulphan, fludarabine and cyclophosphamide are given as a highly lymphocytotoxic combination.
Patients with t(4;11) have so far not benefited from allogeneic SCT. 15 Since, however, the results of the treatment with chemotherapy only are not satisfying, an allogeneic SCT with an irradiation-free conditioning regimen consisting of busulphan, cyclophosphamide and melphalan will be carried out. This has shown good results in patients with jMML 16 and in AML. However, only MSD in CR1 should be recruited if patients experienced a good prednisone response. 
MSD
Groups are defined by immunophenotype, site of relapse and time point of relapse (very early: o18 months after primary diagnosis, early X18 months after primary diagnosis and o6 months after cessation of front-line therapy, late X6 months after cessation of front-line therapy). 
GvHD prophylaxis and therapy
Locatelli et al 17 have demonstrated that the adaptation and modification of GvHD prophylaxis and therapy has an impact on the occurrence of complications or relapses.
However, the results of most paediatric SCT studies cannot directly be compared with each other, since they often differ strongly in the conditioning, GvHD prophylaxis and therapy, as well as different pre-treatments.
One main goal of this study therefore is to apply a riskadjusted GvHD prophylaxis and a standardised GvHD therapy. In MSD, GvHD prophylaxis consists of cyclosporin A only, and in MD transplantation MTX and additional immunosuppression with ATG is applied. In transplantation from MMD, a CD34-positive selection without pharmacological immunosuppression is performed. Furthermore, precise HLA typing will enable to determine incompatibilities on allele levels between recipient and donor, and to investigate the clinical value of these findings.
The present prospective study evaluates the efficacy of allogeneic SCT in children with ALL in first, second or any following remission. Other therapy options are the continuation of chemotherapy or the application/designing of pilot protocols for certain situations (eg no remission, severe previous toxicity).
Especially for subgroups for which retrospective analyses do not render evidence of an improvement of the overall survival, a prospective evaluation of late effects after allogeneic SCT or chemotherapy only is of major importance for further decisions.
